Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Axiom Investors LLC DE

Key Points

• Axiom Investors LLC DE reduced its stake in Supernus Pharmaceuticals, Inc. by 22.2%, selling 15,521 shares and owning approximately 0.10% of the company valued at $1,781,000.
• Insider trading was notable, with CEO Jack A. Khattar selling 140,000 shares for over $5.88 million, resulting in an 11.96% decrease in his ownership.
• Analyst ratings for Supernus Pharmaceuticals have improved, with Zacks Research upgrading it from a "strong sell" to a "hold," and other analysts giving it a consensus rating of "Moderate Buy".

Axiom Investors LLC DE lessened its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 22.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 54,375 shares of the specialty pharmaceutical company's stock after selling 15,521 shares during the quarter. Axiom Investors LLC DE owned approximately 0.10% of Supernus Pharmaceuticals worth $1,781,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Raiffeisen Bank International AG purchased a new position in Supernus Pharmaceuticals in the fourth quarter valued at $25,000. Financial Management Professionals Inc. purchased a new position in Supernus Pharmaceuticals in the first quarter valued at $30,000. Versant Capital Management Inc increased its holdings in Supernus Pharmaceuticals by 6,931.3% in the first quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company's stock valued at $37,000 after buying an additional 1,109 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in Supernus Pharmaceuticals in the first quarter valued at $41,000. Finally, GF Fund Management CO. LTD. acquired a new position in Supernus Pharmaceuticals in the fourth quarter valued at $42,000.

Insider Buying and Selling at Supernus Pharmaceuticals

In other news, Director Bethany Sensenig sold 5,369 shares of the stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $42.25, for a total transaction of $226,840.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Jack A. Khattar sold 6,322 shares of the stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $46.29, for a total transaction of $292,645.38. Following the sale, the chief executive officer owned 1,111,983 shares of the company's stock, valued at $51,473,693.07. This trade represents a 0.57% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 241,506 shares of company stock valued at $10,466,794. Corporate insiders own 8.80% of the company's stock.

Analysts Set New Price Targets

Several research firms have issued reports on SUPN. Zacks Research upgraded shares of Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 19th. Wall Street Zen upgraded shares of Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Piper Sandler upped their price objective on shares of Supernus Pharmaceuticals from $36.00 to $40.00 and gave the company a "neutral" rating in a research note on Friday, August 29th. Finally, Cantor Fitzgerald upped their price objective on shares of Supernus Pharmaceuticals from $42.00 to $46.00 and gave the company an "overweight" rating in a research note on Wednesday, August 6th. Two investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $43.00.

Supernus Pharmaceuticals Trading Down 2.6%

Shares of SUPN traded down $1.20 during mid-day trading on Friday, hitting $45.46. 415,075 shares of the company's stock were exchanged, compared to its average volume of 595,633. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $29.16 and a fifty-two week high of $46.78. The firm has a market capitalization of $2.55 billion, a P/E ratio of 39.53 and a beta of 0.79. The business's 50 day moving average is $39.42 and its two-hundred day moving average is $34.62.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.